Strategy and progress of postoperative adjuvant treatment in hepatocellular carcinoma
10.3760/cma.j.cn115396-20240229-00051
- VernacularTitle:肝细胞癌术后辅助治疗的策略与进展
- Author:
Yuan CHENG
1
;
Weidong JIA
Author Information
1. 中国科学技术大学附属第一医院（安徽省立医院）普通外科，合肥 230001
- Keywords:
Carcinoma, hepatocellular;
Neoadjuvant therapy;
Recurrence;
Prognosis
- From:
International Journal of Surgery
2024;51(4):236-240
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma is a significant disease that seriously threatens the life and health of our people, and chronic hepatitis B virus infection is the most important cause of hepatocellular carcinoma in China. Radical surgery is an essential treatment for hepatocellular carcinoma patients who are expected to achieve long-term survival. However, the high recurrence and metastasis rate after surgery significantly affects the long-term prognosis. Postoperative recurrence of hepatocellular carcinoma is characterized by a bimodal pattern, with early recurrence leading to higher mortality and poorer survival prognosis. Postoperative adjuvant therapy can help to reduce the recurrence rate and improve the overall efficacy, but there is no standardized postoperative adjuvant therapy regimen at home and abroad. Studies have shown that antiviral therapy, interventional therapy, targeted therapy, immunotherapy, radiation therapy, and traditional Chinese medicine may have a specific effect on reducing the recurrence of hepatocellular carcinoma after surgery and prolonging overall survival. Key issues such as how to accurately assess and screen the population with a high risk of postoperative recurrence of hepatocellular carcinoma, select the best postoperative adjuvant treatment modality and timing and determine the duration of postoperative adjuvant treatment still need to be confirmed by high-quality fundamental research breakthroughs and multicenter clinical randomized controlled studies. In this article, the authors will discuss the characteristics of postoperative recurrence of hepatocellular carcinoma, the selection of adjuvant treatment strategies, and the problems faced based on the latest research progress and in light of the reality of hepatocellular carcinoma occurrence in China.
